Convertible preferred stock is a popular financing instrument used by companies to fund research and development (R&D) initiatives. This type of stock offers investors the option to convert their preferred shares into common shares of the company at a predetermined conversion ratio. By issuing convertible preferred stock, companies can raise capital for R&D activities while providing investors with the potential for future equity participation. Several notable examples of companies that have utilized convertible preferred stock for funding their R&D initiatives are discussed below.
1. Tesla Inc.:
Tesla, the renowned electric vehicle manufacturer, has leveraged convertible preferred stock to support its R&D efforts. In 2013, Tesla issued $1.38 billion in convertible senior notes to finance its expansion plans and R&D activities. These notes were convertible into Tesla common stock at a premium, providing investors with an opportunity to benefit from the company's growth potential.
2. Moderna Inc.:
Moderna, a leading biotechnology company specializing in mRNA therapeutics, has utilized convertible preferred stock to fund its R&D initiatives. In 2018, Moderna raised $500 million through a
private placement of convertible preferred stock. The funds were primarily allocated towards advancing its pipeline of mRNA-based drugs and vaccines, including those for infectious diseases and rare genetic disorders.
3. Square Inc.:
Square, a prominent financial technology company, has employed convertible preferred stock as a means to finance its R&D endeavors. In 2014, Square raised $150 million through the issuance of convertible preferred stock to support its product development and innovation efforts. The stock offered investors the option to convert their shares into common stock at a predetermined conversion price.
4. Virgin Galactic Holdings Inc.:
Virgin Galactic, a pioneering space tourism company, has utilized convertible preferred stock to fund its ambitious R&D initiatives in the aerospace industry. In 2020, Virgin Galactic raised $460 million through the issuance of convertible preferred stock. The proceeds were earmarked for advancing the development of its space vehicles and
infrastructure, enabling the company to offer commercial space travel experiences.
5. Moderna Therapeutics Inc. (now Moderna Inc.):
Moderna Therapeutics, before its transformation into Moderna Inc., employed convertible preferred stock to fund its groundbreaking mRNA-based drug development programs. In 2015, the company raised $450 million through a private placement of convertible preferred stock. These funds were instrumental in supporting the research and development of Moderna's mRNA therapies for various diseases, including cancer, infectious diseases, and rare genetic disorders.
These examples highlight how companies across different industries have utilized convertible preferred stock as a financing tool to fuel their R&D initiatives. By issuing convertible preferred stock, these companies have attracted investors who are willing to provide capital in
exchange for potential equity upside. This approach allows companies to secure funding for their R&D activities while aligning the interests of investors with the company's long-term growth prospects.